Hi , This week we bring you the hottest bio-designed fashion trends, new leadership for Sherlock Biosciences, our first-ever neurotech-focused conference track, and much more!
NeuroTech Takes the Stage at SynBioBeta!
Is neurotech the next stage of human evolution? Could integrated neural devices help cure mental illness, paralysis, or even increase our memory capacity? For the first time ever, SynBioBeta is presenting an entire track of neurotech sessions in partnership with our friends at Paradromics!
LanzaTech x lululemon: Fashion Gets A Whole New Look
Our friends at LanzaTech have just announced a major new partnership with global athleticwear brand, lululemon. The companies will create the world’s first yarn and fabric using recycled carbon emissions that would otherwise be emitted to the atmosphere as pollution. Congratulations to the entire LanzaTech team, it’s so exciting to see what we dreamed of building with biology come to life!
Listen: Built with Biology Spaces
Join us today for the Built with Biology show on Twitter Spaces at 8 am PT! Spaces is an audio-only platform—all you need is a Twitter handle and the Twitter app on your phone.
Today’s show welcomes Stephanie Michelsen, co-founder and CEO of Jellatech, to discuss animal-free collagen and gelatin and how to rapidly scale sustainable alternatives for animal-based ingredients.
Spotlight: Mushrooms Go High-Fashion with Bolt Threads
Leather is an amazingly versatile material. But getting leather from animals is a labor-intensive and toxic process. Now biomaterials company, Bolt Threads, is reinventing this classic material with mycelium! Soft, sustainable, animal-friendly —and stylish!— mycelium leather is taking sustainable fashion
to a whole new level. Click here to listen to the episode!
Biology meets cloud computing and AI: Unilever partners with Arzeda to harness the power of computer designed enzymes. The multi-year partnership aims to discover new enzymes that will help to transform the sustainability and performance of cleaning and laundry products.
Cellares announced that Poseida Therapeutics will provide insight into autologous and allogeneic CAR-T workflows, as well as emerging programs that include TCR-T, genetically modified NK cells, and other cell therapy manufacturing workflows.
Caribou Biosciences files for a $100 million initial public offering. They believe their technology has broad potential to generate gene and cell therapies in oncology and in therapeutic areas beyond oncology.
Finding the right enzyme for a new drug or additive is a drawn out and almost random process — which Allozymes aims to change with a new system that could set a new standard in the industry, and has raised a $5 million seed round to commercialize.
